1,5-Anhydro-D-Fructose Reductase (AKR1CL2) Antibody
364€ (100 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
1,5-Anhydro-D-Fructose Reductase (AKR1CL2) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx230264
tested applications
ELISA, WB, IF/ICC
Description
AKR1CL2 Antibody is a Rabbit Polyclonal against AKR1CL2.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | 1,5-Anhydro-D-Fructose Reductase (AKR1CL2) |
| Host | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Recommended Dilution | WB: 1/500 - 1/5000, IF/ICC: 1/10 - 1/100. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purity | ≥ 95% (SDS-PAGE) |
| Purification | Purified by immunogen affinity chromatography. |
| Size 1 | 100 µg |
| Form | Liquid |
| Tested Applications | ELISA, WB, IF/ICC |
| Buffer | PBS, pH 7.3, with 0.02% sodium azide and 50% glycerol. |
| Availability | Shipped within 5-12 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q96JD6 |
| Alias | AKR1E2,AKR1CL2,AKRDC1 |
| Background | Antibody anti-AKR1E2 |
| Status | RUO |
| Note | Concentration: 2 mg/ml - Validity: 12 months. |
Descripción
AKR1E2 is a less characterized member of the aldo-keto reductase superfamily but is known to catalyze the reduction of various aldehydes and ketones, contributing to cellular detoxification and redox balance. AKR1E2 has a broad substrate specificity, metabolizing reactive aldehydes such as those derived from lipid peroxidation (4-HNE) and environmental toxins. Its enzymatic activity protects cells from oxidative stress and damage caused by reactive carbonyl species (RCS), linking it to cellular defense mechanisms. While its tissue-specific expression and physiological roles are still being elucidated, AKR1E2 likely plays a role in liver and kidney detoxification processes. Emerging evidence suggests its involvement in redox regulation and energy metabolism under stress conditions. Dysregulation of AKR1E2 may contribute to oxidative stress-associated diseases, including neurodegeneration, cardiovascular disease, and cancer, where impaired detoxification exacerbates cellular damage. Further studies are needed to clarify its unique functions and therapeutic potential.
